A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment (NCT05708352)
A Randomized Controlled Phase 2 Study of the Ketogenic Diet Versus Standard Dietary Guidance for Patients With Newly Diagnosed Glioblastoma in Combination With Standard-of-care Treatment
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 2, randomized two-armed, multi-site study of 170 patients with newly diagnosed glioblastoma multiforme. Patients will be randomized 1:1 to receive Keto Diet, or Standard Anti-Cancer Diet. All patients will receive standard of care treatment for their glioblastoma. The Keto Diet intervention will be for an 18-week period and conducted by trained research dietitians. Daily ketone and glucose levels will be recorded to monitor Keto Diet adherence. This two-armed randomized multi-site study aims to provide evidence to support the hypothesis that a Keto Diet vs. Standard Anti-Cancer Diet improves overall survival in newly diagnosed glioblastoma multiforme patients who receive standard of care treatment.
Who can join: Review the eligibility criteria below.
Location: Cedars-Sinai Medical Center — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
- Keto Diet (BEHAVIORAL)
- Standard Anti-Cancer Diet (BEHAVIORAL)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (5 Sites)
- Cedars-Sinai Medical Center — Los Angeles, California
- University of California, San Francisco — San Francisco, California
- Pacific Neuroscience Institute / Saint John's Cancer Institute — Santa Monica, California
- Duke University — Durham, North Carolina
- Medical College of Wisconsin — Milwaukee, Wisconsin
📞 Contact the Study Coordinator
Phone: (310) 423-5842
Email: GroupCancerTrialInformation@cshs.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Glioblastoma Multiforme
- A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme — Iowa City, Iowa
- Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM) — Baltimore, Maryland
- Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme — Washington D.C., District of Columbia
- A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM — Tucson, Arizona
- Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients — Phoenix, Arizona
- Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM — Stanford, California
Explore by condition: All Glioblastoma Multiforme clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.